Pharming NV logo

PHARM - Pharming NV Share Price

€1.08 -0.0  -2.5%

Last Trade - 12/04/21

Mid Cap
Market Cap £612.0m
Enterprise Value £581.5m
Revenue £161.1m
Position in Universe 295th / 847
Unlock PHARM Revenue
Relative Strength (%)
1m -4.25%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
10.8 15.9 89.6 135.1 169 185.7 205.5 248.1 +76.5%
+29.5 -9.6 +56.8 +42.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, PharmingGroup N.V. revenues increased 10% to EUR185.7M. Net incomedecreased 9% to EUR33M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Net income was offset byForeign currency results increase from EUR460K to EUR16.8M(expense), Research and development increase of 19% toEUR33.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for PHARM
Graphical History


PHARM Revenue Unlock PHARM Revenue

Net Income

PHARM Net Income Unlock PHARM Revenue

Normalised EPS

PHARM Normalised EPS Unlock PHARM Revenue

PE Ratio Range

PHARM PE Ratio Range Unlock PHARM Revenue

Dividend Yield Range

PHARM Dividend Yield Range Unlock PHARM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PHARM EPS Forecasts Unlock PHARM Revenue
Profile Summary

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since July 2, 1998
No. of Shareholders: n/a
No. of Employees: 212
Sector Healthcare
Industry Pharmaceuticals
Exchange Euronext - Amsterdam
Shares in Issue 638,821,619
Free Float (0.0%)
Eligible for
PHARM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PHARM
Upcoming Events for PHARM
Frequently Asked Questions for Pharming NV
What is the Pharming NV share price?

As of 12/04/21, shares in Pharming NV are trading at €1.08, giving the company a market capitalisation of £612.0m. This share price information is delayed by 15 minutes.

How has the Pharming NV share price performed this year?

Shares in Pharming NV are currently trading at €1.08 and the price has moved by 9.74% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pharming NV price has moved by -14.55% over the past year.

What are the analyst and broker recommendations for Pharming NV?

Of the analysts with advisory recommendations for Pharming NV, there are there are currently 3 "buy" , 0 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Pharming NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Pharming NV next release its financial results?

Pharming NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pharming NV dividend yield?

Pharming NV does not currently pay a dividend.

Does Pharming NV pay a dividend?

Pharming NV does not currently pay a dividend.

When does Pharming NV next pay dividends?

Pharming NV does not currently pay a dividend.

How do I buy Pharming NV shares?

To buy shares in Pharming NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pharming NV?

Shares in Pharming NV are currently trading at €1.08, giving the company a market capitalisation of £612.0m.

Where are Pharming NV shares listed? Where are Pharming NV shares listed?

Here are the trading details for Pharming NV:

Country of listing: Netherlands
Exchange: AEX
Ticker Symbol: PHARM
What kind of share is Pharming NV?

Based on an overall assessment of its quality, value and momentum, Pharming NV is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pharming NV share price forecast 2021?

Shares in Pharming NV are currently priced at €1.08. At that level they are trading at 0.516% discount to the analyst consensus target price of 0.00.

Analysts covering Pharming NV currently have a consensus Earnings Per Share (EPS) forecast of 0.075 for the next financial year.

How can I tell whether the Pharming NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharming NV. Over the past six months, the relative strength of its shares against the market has been -6.2%. At the current price of €1.08, shares in Pharming NV are trading at 0.78% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pharming NV PE Ratio?

The Pharming NV PE ratio based on its reported earnings over the past 12 months is 23.08. The shares are currently trading at €1.08.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Pharming NV?

Pharming NV's management team is headed by:

Bruno Giannetti - MGB
Jonh Ward - SUB
Sijmen de Vries - CMG
Juergen Ernst - VSU
Aad de Winter - SUB
Anne-Marie de Groot - SVP
Paul Sekhri - CSU
Stephen Toor - SVP
Mireille Sanders - SVP
Debora Jorn - SUB
Jeroen Wakkerman - CFO
Who are the major shareholders of Pharming NV?

Here are the top five shareholders of Pharming NV based on the size of their shareholding:

Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund
Percentage owned: 2.91% (18.6m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 2.86% (18.2m shares)
Goldman Sachs Asset Management, L.P. Investment Advisor
Percentage owned: 2.46% (15.7m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.41% (9.01m shares)
Healthinvest Partners AB Investment Advisor/Hedge Fund
Percentage owned: 1.11% (7.10m shares)
Similar to PHARM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.